for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Theravance Biopharma Inc

TBPH.OQ

Latest Trade

17.05USD

Change

-0.14(-0.81%)

Volume

98,069

Today's Range

16.61

 - 

17.27

52 Week Range

14.48

 - 

31.54

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
17.19
Open
17.19
Volume
98,069
3M AVG Volume
7.84
Today's High
17.27
Today's Low
16.61
52 Week High
31.54
52 Week Low
14.48
Shares Out (MIL)
63.98
Market Cap (MIL)
1,090.88
Forward P/E
-3.80
Dividend (Yield %)
--

Latest Developments

More

Theravance Biopharma, Inc. Reports Third Quarter 2020 Financial Results And Provides Business Update

Theravance Biopharma, Inc. Reports Second Quarter 2020 Financial Results And Provides Business Update

Theravance Announces First Patient Dosed In Phase 2 Study Of TD-0903 For Acute Lung Injury By COVID-19

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Theravance Biopharma Inc

Theravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company's pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. Its commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Its Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease. Its neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases.

Industry

Biotechnology & Drugs

Contact Info

UGLAND HOUSE, SOUTH CHURCH STREET

KY1-1104

Cayman Islands

+1.345.6508086000

http://www.theravance.com

Executive Leadership

Rick E. Winningham

Chairman of the Board, Chief Executive Officer

Andrew Hindman

Chief Financial Officer, Senior Vice President

Ann B. Brady

President - Theravance Biopharma Ireland Limited

Bradford J. Shafer

Executive Vice President, General Counsel, Secretary

Brett K. Haumann

Senior Vice President, Clinical Development and Chief Medical Officer

Key Stats

2.22 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.1K

2019

0.1K

2020(E)

0.1K
EPS (USD)

2017

-5.300

2018

-3.990

2019

-4.250

2020(E)

-4.520
Price To Earnings (TTM)
--
Price To Sales (TTM)
13.20
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-76.62
Return on Equity (TTM)
-59.57

Latest News

Latest News

BRIEF-Theravance Biopharma Appoints Deepika R. Pakianathan To Board Of Directors

* THERAVANCE BIOPHARMA APPOINTS DEEPIKA R. PAKIANATHAN, PH.D. TO BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

BRIEF-Theravance Announces First Patient Dosed In Phase 2 Study Of TD-0903 For Acute Lung Injury By COVID-19

* THERAVANCE BIOPHARMA ANNOUNCES FIRST PATIENT DOSED IN PHASE 2 STUDY OF TD-0903 FOR THE TREATMENT OF HOSPITALIZED PATIENTS WITH ACUTE LUNG INJURY CAUSED BY COVID-19

BRIEF-GSK Prices $280.3 Mln Notes Due 2023 Exchangeable Into Theravance Biopharma Shares

* GSK - GSK PRICES $280.3 MILLION SENIOR NOTES DUE 2023 EXCHANGEABLE INTO THERAVANCE BIOPHARMA ORDINARY SHARES Source text for Eikon: Further company coverage:

BRIEF-GSK Proposes Unregistered Offering Of Senior Notes Exchangeable Into Theravance Biopharma Shares

* ANNOUNCES PROPOSED UNREGISTERED OFFERING OF SENIOR NOTES EXCHANGEABLE INTO THERAVANCE BIOPHARMA ORDINARY SHARES

BRIEF-Theravance Biopharma Says Received From Innoviva Draft TRC Quarterly Financial Plan

* THERAVANCE BIOPHARMA - ON JUNE 1, 2020 RECEIVED FROM INNOVIVA DRAFT TRC QTRLY FINANCIAL PLAN FOR QUARTER ENDING SEPT 30, 2020

BRIEF-Theravance Biopharma Announces First Subject Dosed In Phase 1 Study Of Td-0903, In Development For Treatment Of Hospitalized Patients With Acute Lung Injury Caused By COVID-19

* THERAVANCE BIOPHARMA ANNOUNCES FIRST SUBJECT DOSED IN PHASE 1 STUDY OF TD-0903, IN DEVELOPMENT FOR THE TREATMENT OF HOSPITALIZED PATIENTS WITH ACUTE LUNG INJURY CAUSED BY COVID-19 Source text for Eikon: Further company coverage:

BRIEF-Theravance Biopharma Announces Peer-Reviewed Publication Highlighting TD-1473 Program In The Journal Of Crohn's And Colitis

* THERAVANCE BIOPHARMA ANNOUNCES PEER-REVIEWED PUBLICATION HIGHLIGHTING TD-1473 PROGRAM IN THE JOURNAL OF CROHN'S AND COLITIS

BRIEF-Theravance Biopharma Responds To Covid-19 Pandemic By Advancing Td-0903

* THERAVANCE BIOPHARMA RESPONDS TO COVID-19 PANDEMIC BY ADVANCING TD-0903 TO TREAT HOSPITALIZED PATIENTS WITH ACUTE LUNG INJURY

BRIEF-Theravance Biopharma Posts Quarterly Loss Per Share Of $1.17

* THERAVANCE BIOPHARMA, INC. REPORTS FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Theravance Biopharma Announces Pricing Of Public Offering Of Ordinary Shares

* THERAVANCE BIOPHARMA ANNOUNCES PRICING OF PUBLIC OFFERING OF ORDINARY SHARES

BRIEF-Theravance Biopharma Announces Proposed Public Offering Of Ordinary Shares

* THERAVANCE BIOPHARMA ANNOUNCES PROPOSED PUBLIC OFFERING OF ORDINARY SHARES

Mylan and Theravance's COPD treatment gets FDA approval

Theravance Biopharma Inc and partner Mylan NV on Friday won U.S. regulatory approval for their treatment for a chronic lung condition that causes breathing-related problems.

Mylan and Theravance Biopharma's COPD treatment gets FDA approval

Theravance Biopharma Inc and partner Mylan NV on Friday won U.S. regulatory approval for their treatment for a chronic lung condition that causes breathing-related problems.

BRIEF-Theravance Expects To Report Data From Phase 2A Study In nOH Patients By July End

* THERAVANCE BIOPHARMA TO HOST KEY OPINION LEADER EVENT FOCUSED ON THE UNMET MEDICAL NEED IN THE TREATMENT OF NEUROGENIC ORTHOSTATIC HYPOTENSION

BRIEF-Theravance Biopharma Q4 Revenue $4.5 Million

* THERAVANCE BIOPHARMA, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Theravance Biopharma And Mylan Announce FDA Acceptance Of New Drug Application For Revefenacin

* THERAVANCE BIOPHARMA AND MYLAN ANNOUNCE FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR REVEFENACIN (TD-4208) IN ADULTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

BRIEF-Theravance, Mylan Announce FDA Acceptance Of Marketing Application For Revefenacin

* THERAVANCE BIOPHARMA AND MYLAN ANNOUNCE FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR REVEFENACIN (TD-4208) IN ADULTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE Source text for Eikon: Further company coverage:

BRIEF-Theravance Biopharma ‍Files Supplemental NDA With U.S. FDA For Use Of Trelegy Ellipta​

* THERAVANCE BIOPHARMA HIGHLIGHTS SUBMISSION OF LANDMARK IMPACT DATA TO FDA TO SUPPORT EXPANDED LABEL FOR TRELEGY ELLIPTA

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up